TỔNG QUAN HỆ THỐNG PHÂN TÍCH CHI PHÍ – HIỆU QUẢ CỦA ALECTINIB TRONG ĐIỀU TRỊ UNG THU PHỔI KHÔNG TẾ BÀO NHỎ ALK DƯƠNG TÍNH 

Summary
Lung cancer is the leading cause of cancer death worldwide, of which, ALK positive non-small cell lung cancer (ALK+ NSCLC) accounts for 85 % of all new lung cancer diagnoses. The costeffectiveness of alectinib is an important basis for considering the feasibility of using drugs in practice. Systematic review of cost – effectiveness analyses of alectinib in ALK+ NSCLC has been conducted under the guidance of PRISMA based on database Pubmed and Cochrane with suitable keywords and phrases. The quality of studies was assessed using CHEERS checklist. Data on research characteristics and results was analyzed, in which ICER/QALY was converted to the same currency in USD (2019). 6 articles satisfying the selection criteria were included in review. It has been shown that the quality of these research was good. ICER/QALY is valued between $33.021 – $130.339 when compared alectinib with ceritinib and $41.002 – $105.968 between alectinib and crizotinib. 3 out of 6 research concluded that alectinib was cost – effective compared to ceritinib and crizotinib. In conclusion, a systematic review of studies recorded different results on the cost – effectiveness of alectinib between countries and compared drugs.

Keywords: Cost – effectiveness, lymphoma kinase – positive non-small cell lung cancer, systematic review.

Đầu trang

Tải